Food Safety Incidents

Products offered as being slimming has been detected in Dietary supplement glamorous black deluxe.

Written by SGS Digicomply Editorial Team | Feb 27, 2026 11:00:00 PM

Food Safety Incident Report

On February 12, 2026, a significant food safety incident was reported concerning a dietary supplement marketed for slimming purposes. The Brazilian Health Regulatory Agency (ANVISA) has identified concerns related to the product, which is described generically as a dietary supplement. This incident highlights the importance of vigilance in the dietary supplement market, particularly for products that claim to aid in weight loss.

The origin of the issue has been traced back to Brazil, where regulatory authorities are taking necessary measures to ensure consumer safety. It is crucial for consumers to be aware of the potential risks associated with dietary supplements, especially those that promise quick results in weight management. Such products may not always undergo rigorous testing for safety and efficacy, leading to possible health hazards.

Consumers are advised to exercise caution when selecting dietary supplements and to consult healthcare professionals before starting any new regimen. Regulatory bodies play a vital role in monitoring and controlling the safety of food products, including dietary supplements, to protect public health.

As this incident unfolds, further information will be provided by health authorities to ensure that consumers are informed and can make safe choices regarding their dietary supplement intake.

  • Incident: Products offered as being slimming has been detected in Dietary supplement glamorous black deluxe.
  • Date: 2026-02-12
  • Product: Dietary supplement glamorous black deluxe
  • Market: Available to SGS Digicomply users only. Explore the platform (for enterprises, no individual plans)
  • Origin of issue: Brazil
  • Hazard: Available to SGS Digicomply users only. Explore the platform (for enterprises, no individual plans)
  • Incident Category: Control
  • Source: Brazilian Health Regulatory Agency - ANVISA